Company Profiles

driven by the PitchBook Platform

ADC Therapeutics

ADC Therapeutics
2012 FOUNDED
PRIVATE STATUS
11-50 EMPLOYEES
Early Stage VC LATEST DEAL TYPE
$105M LATEST DEAL AMOUNT
$275M TOTAL AMOUNT RAISED
Description

Developer of antibody drug conjugate (ADC) products. The company is developing proprietary antibody and non-antibody drug conjugate products that target hematological cancers and tumor cells. It specializes in the development of targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Drug Delivery
Primary Office
Route de la Corniche 3B
1066 Epalinges
Switzerland

+41 (0)21 653 0200
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ADC Therapeutics’s full profile, request a free trial.

ADC Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 18-Oct-2016 $105M $275M Completed Clinical Trials - Phase 1
3. Early Stage VC 02-Sep-2015 0000 00000 Completed Startup
2. Early Stage VC 15-Oct-2013 $40M $90M Completed Startup
1. Early Stage VC 26-Mar-2012 $50M $50M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

ADC Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
AstraZeneca Corporation Minority 000 0000 000000 0
Auven Therapeutics PE/Buyout Minority 000 0000 000000 0
Cancer Research Technology Venture Capital Minority 000 0000 000000 0
EG Capital Advisors Asset Manager Minority 000 0000 000000 0
ET Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

ADC Therapeutics Executive Team (13)

Name Title Board
Seat
Contact
Info
Chris Martin Ph.D Chief Executive Officer & Board Member
Michael Forer Vice Chairman, Executive Vice President & Chief Financial Officer
Stuart Barlow Chief Accounting Officer & Group Treasurer
Stephane Henchoz Director, Finance
Maria Cincotta Executive Director of Clinical Operations
You’re viewing 5 of 13 executives. Get the full list »

ADC Therapeutics Board Members (9)

Name Representing Role Since Contact
Info
Bahija Jallal Ph.D MedImmune Board Member 000 0000
Barrie Ward Ph.D Self Board Member 000 0000
Chris Martin Ph.D ADC Therapeutics Chief Executive Officer & Board Member 000 0000
Hans-Peter Wild Self Board Member 000 0000
Jacques Theurillat Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »